Clinical trial hits new target in war on breast cancer
Breast cancers are defined by their drivers – estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer ...
Cancer
Dec 03, 2012 |
5 / 5 (2) |
0
|
Study role testosterone may play in triple negative breast cancer
Could blocking a testosterone receptor lead to a new way to treat an aggressive form of breast cancer? That's a question researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) are exploring. ...
Cancer
Mar 23, 2012 |
5 / 5 (1) |
0
|
Researchers uncover multiple faces of deadly breast cancer
An international team of scientists, including four at Simon Fraser University, has made a discovery that will change the way the most deadly form of breast cancer is treated.
Cancer
Apr 04, 2012 |
5 / 5 (1) |
1
|
New target, new drug in breast cancer
Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen (AR) ...
Cancer
Jun 04, 2012 |
5 / 5 (1) |
0
Genome packaging: Key to breast cancer development
Cancer is a complex disease and only thanks to advances in genomic techniques have researchers begun to understand, at a cellular and molecular level, the mechanisms which are disrupted in cancer cells. This ...
Cancer
Nov 22, 2012 |
5 / 5 (1) |
0
The HER2 paradox: HER2-positive stem cells found in HER2-negative breast cancer
A multicenter study led by researchers at UC Davis describes new, paradoxical characteristics of the most common type of breast cancer. The findings shed light on how the disease can evade treatment and could improve diagnosis ...
Cancer
Dec 14, 2012 |
5 / 5 (1) |
0
Healthy lifestyle during menopause may decrease breast cancer risk later on
Obese, postmenopausal women are at greater risk for developing breast cancer and their cancers tend to be more aggressive than those in lean counterparts. A University of Colorado Cancer Center study published in the December ...
Cancer
Dec 19, 2012 |
5 / 5 (1) |
0
Studies show increasing evidence that androgen drives breast cancer
Estrogen and progesterone receptors, and the gene HER2 – these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.
Cancer
Apr 10, 2013 |
5 / 5 (1) |
0
Researchers identify new pathway, enhancing tamoxifen to tame aggressive breast cancer
Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary ...
Cancer
Apr 23, 2013 |
5 / 5 (1) |
0
ECE: Gene variants linked to reduced male fertility
(HealthDay)—Particular gene variants of follicle stimulating hormone (FSH) and its receptor are associated with significantly reduced fertility in men, according to a study presented at the annual European ...
Genetics
May 03, 2013 |
5 / 5 (1) |
0
